Literature DB >> 8412364

Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study.

P Wischmeyer1, J H Pemberton, S F Phillips.   

Abstract

Nonspecific, idiopathic inflammation of ileal pouch mucosa ("pouchitis") after ileal pouch-anal anastomosis is a common complication of this surgical approach. The epithelium of the pouch is ileal, but variable degrees of colonic metaplasia are natural sequelae of construction of such a pouch. One hypothesis is that pouchitis is caused by a deficiency of epithelial nutrition. Thus, a lack of butyric acid (the principal metabolic fuel of colonocytes) or of glutamine (the main fuel of enterocytes) may develop. In this study, our aims were to determine the concentration of total short-chain fatty acids in random stool samples obtained from patients with an ileal pouch-anal anastomosis with and without pouchitis and to test the therapeutic effects of butyrate and glutamine suppositories on pouchitis. During the study, all conventional therapy for pouchitis was discontinued. For 21 days, 9 patients participated in a butyrate trial, and 10 patients were treated with glutamine. Total concentrations of fecal short-chain fatty acids were significantly less in patients with pouchitis than in those without pouchitis. During treatment, 6 of the 10 patients who received glutamine had no recurrence of symptoms, but only 3 of the 9 patients who received butyrate responded similarly. Hence, further studies of glutamine in the treatment of pouchitis seem warranted.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8412364     DOI: 10.1016/s0025-6196(12)62270-8

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  24 in total

Review 1.  Medical management of postoperative complications of inflammatory bowel disease: pouchitis and Crohn's disease recurrence.

Authors:  J P Achkar; B Shen
Journal:  Curr Gastroenterol Rep       Date:  2001-12

Review 2.  Diagnosis and management of pouchitis and ileoanal pouch dysfunction.

Authors:  Udayakumar Navaneethan; Bo Shen
Journal:  Curr Gastroenterol Rep       Date:  2010-12

3.  Diagnosis and treatment of ileal pouch diseases in patients with underlying ulcerative colitis.

Authors:  Bo Shen; Bret Lashner
Journal:  Curr Treat Options Gastroenterol       Date:  2006-02

4.  Sodium butyrate-induced liver-type alkaline phosphatase activity in a small intestinal epithelial cell line, IEC6.

Authors:  K Fukushima; I Sasaki; H Hasegawa; K Takahashi; H Naito; Y Funayama; S Matsuno
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

5.  Application of a spontaneously closed protective stoma in an ileal pouch-anal anastomosis: a preliminary study.

Authors:  Jinhai Wang; Bingxin Ke; Jianjiang Lin; Jiahe Xu; Wenbin Chen
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 6.  Medical and Surgical Management of Pediatric Ulcerative Colitis.

Authors:  José M Cabrera; Thomas T Sato
Journal:  Clin Colon Rectal Surg       Date:  2018-02-25

Review 7.  Surgical prophylaxis of pouchitis in ulcerative colitis.

Authors:  Giuseppe Brisinda; Serafino Vanella; Venanzio Valenza; Anna Crocco; Germano Perotti; Daniela Di Giuda; Giorgio Maria
Journal:  Dig Dis Sci       Date:  2010-12-03       Impact factor: 3.199

Review 8.  Pouchitis: a practical guide.

Authors:  A Hillary Steinhart; Ofer Ben-Bassat
Journal:  Frontline Gastroenterol       Date:  2013-11-12

9.  Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.

Authors:  T Mimura; F Rizzello; U Helwig; G Poggioli; S Schreiber; I C Talbot; R J Nicholls; P Gionchetti; M Campieri; M A Kamm
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

10.  Prophylactic administration of topical glutamine enhances the capability of the rat colon to resist inflammatory damage.

Authors:  Eran Israeli; Eduard Berenshtein; Dov Wengrower; Larisa Aptekar; Ron Kohen; Gershom Zajicek; Eran Goldin
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.